Роль российских ученых в разработке сибиреязвенных вакцин

М В Супотницкий, И. В. Борисевич, В И Климов, А Н Шевцов, М Ю Луб, Alexey TumanovACTUAL 2015

Introduction

Anthrax, caused by Bacillus anthracis, remains a formidable pathogen due to its ability to form highly resilient spores. These spores can persist in the environment for decades or be aerosolized, posing a significant threat to both public health and biosecurity. The quest for an effective vaccine has spanned over a century, with Russian and Soviet scientists playing a pivotal role in developing strategies that differ significantly from Western approaches. This review examines the evolution of anthrax vaccines, emphasizing the Russian focus on live unencapsulated spore vaccines and "combined" formulations.

Historical Evolution of Anthrax Vaccines

The development of anthrax vaccines can be categorized into five distinct stages, beginning with early attempts at bacterial attenuation.

1. Early Attenuation

The first stage involved heat-based weakening of encapsulated strains. Pioneers like Louis Pasteur and the Russian scientist L.S. Tsenkovsky demonstrated that attenuated bacteria could induce immunity in livestock. However, these early vaccines often retained enough virulence to be dangerous for human use.

Historical depiction of early anthrax vaccination efforts, marking the first stage of vaccine development.

2. Chemical Components and Toxin Mechanism

As molecular biology advanced, researchers identified the primary virulence factors of B. anthracis: the capsule and the tripartite toxin (Protective Antigen [PA], Edema Factor [EF], and Lethal Factor [LF]). Western vaccinology shifted toward "chemical" vaccines based primarily on the Protective Antigen.

The molecular mechanism of anthrax toxin entry and action, highlighting the role of Protective Antigen (PA) in cell binding and pore formation.

The toxin mechanism involves PA binding to the Anthrax Toxin Receptor (ATR), followed by cleavage and oligomerization. This complex then transports EF and LF into the cell, leading to increased cAMP levels, edema, and cell death. While chemical vaccines targeting PA are safer than early live vaccines, they often require frequent boosters and provide limited protection against inhalation anthrax.

The Russian Breakthrough: Live Unencapsulated Spores (STI-1)

A major turning point occurred in the 1930s and 40s when Soviet researchers, led by N.N. Ginsburg and A.L. Tamarin, realized that the bacterial capsule is necessary for disease but not for immunity. This led to the development of the STI-1 strain in 1940. STI-1 is a live, unencapsulated spore vaccine that is safe for humans but far more immunogenic than chemical alternatives. It became a cornerstone of Soviet biodefense, successfully protecting millions of animals and thousands of soldiers during World War II.

Comparative Efficacy and the "Combined" Strategy

The Russian approach emphasizes that "sterilizing immunity" — the ability to prevent the initial colonization and invasion of bacteria — is best achieved through live vaccines. While Western PA-only vaccines target the toxin, they may fail to stop the infection itself, especially in aerosolized exposures.

Russian scientists developed "combined" vaccines that mix live spores (like STI-1) with purified PA. This dual approach triggers a broad cellular immune response while providing immediate toxin neutralization. Data indicates that while live vaccines alone provide 55–65% protection by day 21, the combined vaccine achieves 80–90% protection within just 7–10 days.

Conclusion and Future Directions

The legacy of Russian anthrax research highlights the importance of maintaining diverse vaccine strategies. While recombinant DNA technology offers the promise of safer, more scalable production, challenges such as antigen degradation by host proteases remain. Future efforts should focus on refining the combined vaccine approach and leveraging genetic engineering to enhance the stability and efficacy of next-generation anthrax countermeasures.

Summary updated

BibTeX
@inproceedings{2015,
  author = {М В Супотницкий and И. В. Борисевич and В И Климов and А Н Шевцов and М Ю Луб and Alexey Tumanov},
  title = {{Роль российских ученых в разработке сибиреязвенных вакцин}},
  booktitle = {ACTUAL},
  year = {2015},
}
Figure